One should be considered for post-exposure anti-influenza chemoprophylaxis when: The illness seen shortly after the influenza vaccination. People who vaccine is contraindicated (including anaphylaxis to egg) History of Guillain-Barre Syndrome within weeks of previously admnistered vaccine Unvaccinated in close contact with those high risk of developing influenza complications All residents of long term facilities ot nursing home, including those already vaccinated. Immunocompromised people People who were unable to get vaccine due to shortage, if the person is at high risk of developing complication of influenza. The suggested chemoprophylactic regime is: Oselatmivir PO: a. 3 months to < 1 y/o: 3 mg/kg OD b. > 1 y/o and BW < 15kg: 30mg OD c. 15 - 23 kg: 45mg OD d. 23 - 40 kg: 60mg OD e. > 40kg and adults: 75mg OD Reference: BMJ Best Practice
Mida-Morphine for sedation may vary from other healthcare institution. Preparation available in KKM: 1) Midazolam injection: 5mg/ml, 15mg/3ml 2) Morphine Injection: 10mg/ml Dilute: ||| Midazolam 30mg (6ml) ||| + ||| Morphine 30mg (3ml) ||| in 21ml Normal Saline (qs. 30ml) in 50cc syringe ~ ~ ~ Midoazolam 1mg/ml and Morphine 1mg/ml 1. May give loading dose of 0.05 mg/kg midazolam 2. Start at 0.06 mcg/kg/hr of midazolam 3. Dose range: 0.06 - 2 mg/kg/hr 4. May increase by 1ml/hr every 20 minutes till target RASS -2 to +1 achieved Source: Medication Reconstitution & Medication Dilution Reference 2013 HSAJB